NEC and Biomy Unite for AI-Powered Precision Medicine in Cancer Care

January 14, 2025

NEC Corporation and Biomy, Inc. have joined forces to revolutionize cancer care through the development of AI-powered analytical platforms in digital pathology. This strategic collaboration aims to advance precision medicine, offering tailored treatments for cancer patients and reducing side effects. By combining their respective expertise in AI technology and digital pathology, NEC and Biomy intend to create groundbreaking tools that facilitate the discovery and application of novel pathological biomarkers. This partnership symbolizes a significant stride towards a more advanced and precise approach to cancer diagnosis and treatment, ultimately supporting the enhancement of medical technology and patient outcomes.

Precision medicine represents a new frontier in patient care, where treatments are customized based on individual disease profiles and unique patient characteristics. Within pathology diagnostics, AI and deep learning (DL) algorithms are being extensively explored for their potential to analyze digital pathology images effectively. The aim is to identify biomarkers that can better stratify patients, guiding the selection of optimal treatments and medications. As such, the collaboration between NEC and Biomy is poised to make substantial contributions to the field of healthcare technology.

The Role of NEC Corporation

NEC Corporation, known for its commitment to social value creation, leverages advanced technologies to tackle various societal challenges. With a rich history in healthcare and life sciences, the company’s growth strategy is deeply rooted in these areas. NEC has built a strong foundation in image analysis and other AI technologies, which is complemented by extensive experience in providing medical information systems, such as electronic medical records. This combination of skills and experience positions NEC as a critical player in the development of AI-driven solutions for cancer care.

NEC’s proficiency is further evidenced by its license for manufacturing and marketing Class I medical devices in Japan. This illustrates the company’s capability to navigate stringent regulatory pathways specific to medical devices, including those based on AI/DL technologies. By contributing their advanced AI platforms and regulatory know-how, NEC is poised to support the partnership with Biomy in creating innovative solutions that could enhance the effectiveness and efficiency of cancer treatments. As a result, cancer patients could benefit from more accurate diagnoses and personalized treatment plans tailored to their unique disease profiles.

Biomy’s Contribution to Precision Medicine

Biomy, Inc. is at the forefront of personalized medicine, committed to realizing its potential through the application of pathological AI technology. They have developed DeepPathFinder™, a proprietary cloud-based AI/DL automated digital pathology analytical platform designed to analyze digital pathology images with high precision. DeepPathFinder™ excels in classifying cell and tissue types in specific regions and detecting immune cells such as lymphocytes and plasma cells from hematoxylin and eosin (H&E)-stained images. This capability positions it as an invaluable tool in the field of digital pathology, particularly in identifying biomarkers critical for cancer treatment.

The platform provides unique insights into drug efficacy and prognosis, which significantly enhance the efficiency and accuracy of digital pathology analyses. By leveraging DeepPathFinder™, healthcare professionals can gain better understandings of how various treatments influence cancer progression and patient outcomes. This, in turn, helps in tailoring treatment regimes that are not only more effective but also have fewer side effects. Through its innovative solutions, Biomy plays a crucial role in discovering new pathological biomarkers that support precision medicine and optimize cancer care strategies.

Objectives of the Partnership

At the heart of the collaboration between NEC and Biomy lies the ambition to integrate their advanced AI technologies to achieve multiple objectives aimed at advancing cancer care. One primary goal is to enhance the DeepPathFinder™ platform to discover new pathological biomarkers through sophisticated AI/DL-based digital pathology image analysis. By leveraging data derived from pathological images, the collaboration aims to support precision medicine and treatment planning, particularly in cancer care. These newly discovered biomarkers can provide critical insights that can be used to guide the development and application of personalized treatments.

Another major objective is to offer the resulting AI/DL-driven pathological biomarker discovery tool to pharmaceutical and biotech companies, as well as academic institutions. This tool will allow for the independent exploration of pathological biomarkers from pathology images. Additionally, NEC and Biomy plan to provide comprehensive digital pathological biomarker discovery services. By offering these services, they will support clients in navigating the regulatory landscape and securing approvals for medical devices that utilize the newly identified pathological biomarkers. This holistic approach ensures that the advanced AI/DL technology can be effectively integrated into the clinical setting, enhancing the overall healthcare experience.

Future Developments in AI-Powered Pathology

NEC Corporation and Biomy, Inc. have partnered to transform cancer care by developing AI-based analytics in digital pathology. This strategic collaboration seeks to advance precision medicine, providing individualized treatments for cancer patients and minimizing side effects. By leveraging their expertise in AI and digital pathology, NEC and Biomy aim to create innovative tools that aid in the discovery and application of new pathological biomarkers. This partnership marks a considerable step toward a more sophisticated and accurate method of cancer diagnosis and treatment, ultimately improving medical technology and patient outcomes.

Precision medicine represents an innovative approach in patient care, where treatments are tailored according to individual disease characteristics and patient-specific factors. In pathology diagnostics, AI and deep learning algorithms are being heavily investigated for their efficient analysis of digital pathology images. The goal is to identify biomarkers that can better categorize patients, helping in the selection of the most effective treatments. Consequently, the partnership between NEC and Biomy is expected to significantly impact healthcare technology.

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later